X-ZELL officially incorporated in Singapore

X-ZELL officially incorporated in Singapore Singapore, October 2018 – X-ZELL Inc., only recently named one of Asia’s 20 most innovative health tech start-ups, is coming to Singapore. According to X-ZELL CEO, Dr Sebastian Bhakdi, the rare cell detection specialist’s...

X-ZELL among 16 most innovative health-tech start-ups in Asia

X-ZELL among 16 most innovative health-tech start-ups in Asia Singapore, September 2018 – Galen Growth, a Singapore-based analytics and advisory firm specialising in cutting-edge healthcare technology, has named X-ZELL Inc. as one of the 16 most innovative health...

X-ZELL technology featured in British urology journal

Ground-breaking X-ZELL research featured in BJU International Oxford, August 2018 – X-ZELL Inc. CEO, Dr Sebastian Bhakdi, has published new research into the utility of tumour-derived Circulating Endothelial Cells (tCEC) for the detection of early-stage prostate...

X-ZELL launches global Cryoimmunostaining™ technology trial

Applications for global Cryoimmunostaining™ technology trial now open Bangkok, July 2018 – After successfully completing a series of clinical trials across Southeast Asia, rare cell detection specialist X-ZELL Inc. is now making the company’s patented...

X-ZELL CEO to present at APCC 2018

X-ZELL CEO to present at Asia-Pacific Prostate Cancer Conference Brisbane, July 2018 – X-ZELL Inc. CEO, Dr Sebastian Bhakdi, will use the upcoming Asia-Pacific Prostate Cancer Conference (APCC) in Brisbane next month as a platform to reveal “exciting new insights”...

NUH Singapore and X-ZELL agree on landmark cancer detection study

National University Hospital Singapore and X-ZELL agree on landmark cancer detection study Singapore, June 2018 – The Department of Urology at Singapore’s National University Hospital and X-ZELL Inc. have signed a Letter of Intent (LOI) to jointly conduct a...